Ballew Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Ballew Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$1K	–	408
2018 Q3	$1K	Buy	+1	New	+$2.72K	﹤0.01%	461

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ballew Advisors's TTNP Position: Q4 2018 in Review

Ballew Advisors sold out of Titan Pharmaceuticals (TTNP) in Q4 2018, closing a stake of 1 share — an estimated $1K sold.

Ballew Advisors first reported a position in TTNP in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 26 funds tracked by Wall St. Rank hold TTNP as of Q4 2018.

Ballew Advisors reported no remaining Titan Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 1 Titan Pharmaceuticals share in Q4 2018, an estimated $1K.
Ballew Advisors first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Titan Pharmaceuticals position peaked at $1K in Q3 2018.
26 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.